Q+A: Kalderos CEO Angie Franks Talks Truzo, 340B Program Transparency

Kalderos CEO Angie Franks recently spoke with 340B Report about the current battle over 340B rebate models, among other things.
Health technology company Kalderos has made waves in the 340B world in recent years after emerging as a key player [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Trump’s ‘Most Favored Nation’ Order Could Lower 340B Ceiling Prices, but Key Details Remain Unclear

President Donald Trump's "most favored nation" executive order has unclear effects on the 340B program.
President Donald Trump’s recent executive order directing federal agencies to pursue “most favored nation” (MFN) pricing for prescription drugs could [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

NACHC Raises Concerns About 340B Rebates, Various Stakeholders Meet with Trump Administration on Rebate Guidance

NACHC raised concerns about implementing a 340B rebate model in a June 17 letter sent to CMS Administrator Mehmet Oz and HRSA Administrator Thomas Engels.
A national 340B community health center organization, which has faced criticism for its partnership with a powerful drug industry trade [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Report: 340B Hospitals Face More Federal Oversight, Fare Better in Audits; HRSA Releases Latest Drugmaker Audit

A new AHA analysis found that 340B hospitals face more federal oversight and routinely see higher rates of compliance in federal audits than drugmakers.
Hospitals that participate in the 340B program face more federal oversight and routinely see higher rates of compliance in federal [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

D.C. Federal District Court Dismisses Hospital Lawsuits Over J&J’s Controversial 340B Audit Requests

A Washington D.C. federal judge this week dismissed lawsuits Oregon Health & Science University and four other hospitals filed against HRSA for authorizing J&J to audit their 340B program records.
A Washington D.C. federal court this week threw out five hospital lawsuits challenging the Health Resources and Services Administration (HRSA) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Recap of Recent Webinar: Key Issues and What to Expect Next on 340B in Washington, D.C.

340B Report Publisher & CEO Ted Slafsky hosted a June 18 subscriber-only webinar, featuring Sue Veer, Devon Seibert-Bailey and Peggy Tighe.
Although the bulk of recent 340B-related legislative action has occurred in statehouses across the country, 340B advocates and stakeholders are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Roundup: Updates in Utah and South Dakota

Key briefs were filed in litigation on contract pharmacy access laws in Utah and South Dakota.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AbbVie is 1st Drugmaker to Challenge Colorado’s New 340B Contract Pharmacy Access & Reporting Law

AbbVie filed a June 12 lawsuit in federal court against the state of Colorado that challenges the constitutionality of that state’s contract pharmacy law.
A Chicago-based pharmaceutical giant recently urged a federal court to block Colorado’s contract pharmacy access law—marking the first drug manufacturer [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Appellate Court Fast-Tracks Drugmakers’ Appeal of 340B Rebate Ruling

A federal appellate court in Washington, D.C. will hear two drugmakers' appeal of a lower courts 340B rebate ruling on an expedited schedule.
A federal appellate court in Washington, D.C. is fast-tracking Novartis and Bristol Myers Squibb’s (BMS) appeal of a lower court [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Offers New Details on Medicare Drug Price Negotiations, 340B Advocates Raise Concerns About Impact on Program

340B stakeholders raised concerns about May 12 draft guidance on the IRA Medicare Drug Price Negotiation Program's “manufacturer effectuation of the maximum fair price in 2026, 2027 and 2028,” among other things.
The Centers for Medicare and Medicaid Services (CMS) released new details this week to help stakeholders navigate the Inflation Reduction [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live